Redmond Asset Management’s Dyne Therapeutics DYN Stock Holding History

Redmond Asset Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,500	Closed	-$355K	–	159
2024 Q1	$355K	Hold	12,500	–	–	0.11%	133
2023 Q4	$166K	Sell	12,500 -716	-5%	-$6.99K	0.05%	155
2023 Q3	$118K	Hold	13,216	–	–	0.04%	157
2023 Q2	$149K	Hold	13,216	–	–	0.05%	155
2023 Q1	$152K	Sell	13,216 -110	-0.8%	-$1.43K	0.05%	159
2022 Q4	$154K	Buy	13,326 +158	+1%	+$1.83K	0.06%	164
2022 Q3	$167K	Sell	13,168 -23	-0.2%	-$264	0.06%	164
2022 Q2	$91K	Hold	13,191	–	–	0.03%	180
2022 Q1	$127K	Buy	13,191 +534	+4%	+$4.55K	0.04%	185
2021 Q4	$150K	Buy	12,657 +144	+1%	+$2.02K	0.04%	192
2021 Q3	$203K	Hold	12,513	–	–	0.06%	180
2021 Q2	$263K	Hold	12,513	–	–	0.08%	178
2021 Q1	$194K	Buy	+12,513	New	+$242K	0.06%	186

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Redmond Asset Management's DYN Position: Q2 2024 in Review

Redmond Asset Management sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 12,500 shares — an estimated $355K sold.

Redmond Asset Management first reported a position in DYN in Q1 2021 and held it in 13 quarters. The position peaked at $355K in Q1 2024. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

Redmond Asset Management reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
Redmond Asset Management sold 12,500 Dyne Therapeutics shares in Q2 2024, an estimated $355K.
Redmond Asset Management first reported a position in Dyne Therapeutics in Q1 2021 and held it in 13 quarters.
Redmond Asset Management's Dyne Therapeutics position peaked at $355K in Q1 2024.
193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on Redmond Asset Management's 13F filing for Q2 2024, filed 9 Aug 2024.